Skip to Main Content

Paper Details

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
Nat Cancer
53
2022
ATP, EGFR, EGFR L747S mutation, EGFR T790M, EGFR mutations, EGFR site, EGFR-mutant lung cancer, ERBB family members, Epidermal growth factor receptor, JBJ-09-, JBJ-09-063, L747S, T790M, non-small cell lung cancer, patients, resistant models, tyrosine, tyrosine kinase
Author NameAffiliation
Thomas W GeroDana-Farber Cancer Institute
Thomas W GeroHarvard Medical School
Nathanael S GrayDana-Farber Cancer Institute
Nathanael S GrayStanford University
Nathanael S GrayHarvard Medical School
Nathanael S GrayDana-Farber Cancer Institute
Nathanael S GrayHarvard Medical School
Nathanael S GrayStanford University
Pasi A J??nneLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
Pasi A J??nneDana-Farber Cancer Institute
Pasi A J??nneHarvard Medical School
  • 1 - 11

Datasets

Release 1.2